Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew Grigg

Showing results (61-70 of 132) with videos related to

Pageof 14
Sort By:
JCO Oncology Practice|June 26, 2020
Routine Blood Tests in Asymptomatic Patients With Indolent Lymphoma Have Limited Ability to Detect Clinically Significant Disease ProgressionOliver A Piercey, Zoe Loh, Joanna Chan, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|October 26, 2011
The KIR2DS2/DL2 genotype is associated with adult persistent/chronic and relapsed immune thrombocytopenia independently of FCGR3a-158 polymorphismsJamie P Nourse, Rod Lea, Pauline Crooks, et al.
Haematologica|December 25, 2016
Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphomaAndrew Grigg, Martin J S Dyer, Marcos González Díaz, et al.
Transplantation|April 16, 2004
Non-HLA immunogenetic polymorphisms and the risk of complications after allogeneic hemopoietic stem-cell transplantationCharles Mullighan, Sue Heatley, Kathleen Doherty, et al.
Neuro-Oncology|March 19, 2013
Rituximab is associated with improved survival for aggressive B cell CNS lymphomaGareth Gregory, Ashwini Arumugaswamy, Teresa Leung, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|December 17, 2009
Comparative PET study using F-18 FET and F-18 FDG for the evaluation of patients with suspected brain tumourEddie W F Lau, Katharine J Drummond, Robert E Ware, et al.
Haematologica|November 8, 2011
Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year periodMichelle R Ananda-Rajah, Andrew Grigg, Maria T Downey, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 17, 2011
The effect of folinic acid on methylenetetrahydrofolate reductase polymorphisms in methotrexate-treated allogeneic hematopoietic stem cell transplantsNicholas M Murphy, Mary Diviney, Jeff Szer, et al.
American Journal of Hematology|August 21, 2020
Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapyFarheen Mir, Federico Mattiello, Andrew Grigg, et al.
European Journal of Haematology|May 3, 2018
Prognostic markers in core-binding factor AML and improved survival with multiple consolidation cycles of intermediate-/high-dose cytarabineAshvind Prabahran, Mark Tacey, Shaun Fleming, et al.
Pageof 14

Showing results (61-70 of 132) with videos related to

Sort By:
Pageof 14
JCO Oncology Practice|June 26, 2020
Routine Blood Tests in Asymptomatic Patients With Indolent Lymphoma Have Limited Ability to Detect Clinically Significant Disease ProgressionOliver A Piercey, Zoe Loh, Joanna Chan, et al.
Blood Coagulation & Fibrinolysis : an International Journal in Haemostasis and Thrombosis|October 26, 2011
The KIR2DS2/DL2 genotype is associated with adult persistent/chronic and relapsed immune thrombocytopenia independently of FCGR3a-158 polymorphismsJamie P Nourse, Rod Lea, Pauline Crooks, et al.
Haematologica|December 25, 2016
Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphomaAndrew Grigg, Martin J S Dyer, Marcos González Díaz, et al.
Transplantation|April 16, 2004
Non-HLA immunogenetic polymorphisms and the risk of complications after allogeneic hemopoietic stem-cell transplantationCharles Mullighan, Sue Heatley, Kathleen Doherty, et al.
Neuro-Oncology|March 19, 2013
Rituximab is associated with improved survival for aggressive B cell CNS lymphomaGareth Gregory, Ashwini Arumugaswamy, Teresa Leung, et al.
Journal of Clinical Neuroscience : Official Journal of the Neurosurgical Society of Australasia|December 17, 2009
Comparative PET study using F-18 FET and F-18 FDG for the evaluation of patients with suspected brain tumourEddie W F Lau, Katharine J Drummond, Robert E Ware, et al.
Haematologica|November 8, 2011
Comparative clinical effectiveness of prophylactic voriconazole/posaconazole to fluconazole/itraconazole in patients with acute myeloid leukemia/myelodysplastic syndrome undergoing cytotoxic chemotherapy over a 12-year periodMichelle R Ananda-Rajah, Andrew Grigg, Maria T Downey, et al.
Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|September 17, 2011
The effect of folinic acid on methylenetetrahydrofolate reductase polymorphisms in methotrexate-treated allogeneic hematopoietic stem cell transplantsNicholas M Murphy, Mary Diviney, Jeff Szer, et al.
American Journal of Hematology|August 21, 2020
Follicular Lymphoma Evaluation Index (FLEX): A new clinical prognostic model that is superior to existing risk scores for predicting progression-free survival and early treatment failure after frontline immunochemotherapyFarheen Mir, Federico Mattiello, Andrew Grigg, et al.
European Journal of Haematology|May 3, 2018
Prognostic markers in core-binding factor AML and improved survival with multiple consolidation cycles of intermediate-/high-dose cytarabineAshvind Prabahran, Mark Tacey, Shaun Fleming, et al.
Pageof 14